Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) originally developed for its ability to stimulate the release of growth hormone (GH). It acts through the growth hormone secretagogue/ghrelin receptor pathway and has attracted research interest in GH secretion, endocrine signalling, metabolism, body composition and recovery-related physiology.

Key Research Areas

Growth Hormone Release
Ipamorelin is best known for its ability to stimulate GH secretion. Early experimental research found that it produced potent GH release through a GHRP-like receptor pathway.

Selective GH Signalling
A notable feature of early ipamorelin research was its relative selectivity for GH release. In animal studies, researchers found that, unlike GHRP-2 and GHRP-6, ipamorelin did not significantly increase ACTH or cortisol at the doses examined. This finding is one reason ipamorelin became of interest in growth-hormone secretagogue research.

GH/IGF-1 Axis Research
By stimulating endogenous GH secretion, ipamorelin is relevant to research involving the broader GH/IGF-1 axis, which plays important physiological roles in growth, metabolism and tissue regulation.

Metabolic & Body-Composition Research
Because growth hormone is involved in lipid, carbohydrate and protein metabolism, ipamorelin has generated research interest in areas involving body composition, energy metabolism and GH-associated metabolic signalling. These areas should be described as research interests rather than established clinical benefits.

Ghrelin-Receptor Research
Ipamorelin belongs to the growth hormone secretagogue family associated with the ghrelin receptor (GHS-R1a). Research into this pathway extends beyond GH release to gastrointestinal and metabolic signalling.

Gastrointestinal Research
Ipamorelin has undergone human clinical investigation for postoperative ileus because ghrelin-receptor stimulation can affect gastrointestinal motility. A randomized Phase 2 study evaluated intravenous ipamorelin following bowel surgery, although this did not establish ipamorelin as an approved treatment.